Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Pre-MEASURE: patients with AML in complete remission but high risk of relapse following alloHCT

Measurable residual disease (MRD) prior to allogeneic hematopoietic cell transplantation (alloHCT) is associated with an increased risk of relapse and death in patients with acute myeloid leukemia (AML). In this interview, Christopher Hourigan, MD, DPhil, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, presents the results of Pre-MEASURE, a multicenter evaluation of the prognostic significance of MRD testing prior to allogeneic transplantation for adult patients with AML in first remission. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.